Jupiter Neurosciences Inc (JUNS)

$1.52 -0.04 (-2.56%)
Market Cap 52.95M
Revenue (ttm) 0.00
Net Income (ttm) -2.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 114,900
Avg Vol 369,660
Day's Range N/A - N/A
Shares Out 34.83M
Stochastic %K 71%
Beta N/A
Analysts Sell
Price Target $30.00

Company Profile

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in t...

Industry: Biotechnology
Sector: Healthcare
Phone: 561 406 6154
Address:
1001 North US Highway 1, Suite 504, Jupiter, United States
Thenew52
Thenew52 Sep. 12 at 11:20 PM
$JUNS I'll just say that this is an opportunity for you to buy at a discount. Since I bought when the stock was even lower, I'm calm. So, don't let you continue missing this golden opportunity while I sit back and watch how this will reach $3 in a month.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 8:44 PM
$JUNS It stagnated at 1.52 and people are buying it at that same price. Doesn't that seem like a sign to you?
0 · Reply
Thenew52
Thenew52 Sep. 12 at 8:03 PM
$JUNS Well, we closed in the red after a volatile day. After Monday's pre-market, we'll see if it remains green or if it's best to sell and buy lower.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 3:23 PM
$JUNS Every time it falls it rises and yet you don't buy at the bottom?
0 · Reply
Thenew52
Thenew52 Sep. 12 at 2:31 PM
$JUNS In October it will reach 3 dollars
0 · Reply
Thenew52
Thenew52 Sep. 12 at 2:30 PM
$JUNS They want to buy cheap because they know it will reach $3.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 1:31 PM
$JUNS Opening at 1.59, I think we'll have a green day today.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 10:59 AM
$JUNS It has consolidated at 1.62 for now, but the really good stuff comes at the opening.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 10:04 AM
$JUNS What's going on here? The real price is still above 1.60, but it's 1.51 on Google and here.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 9:19 AM
$JUNS 1.64 pre-market
0 · Reply
Latest News on JUNS
Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

Aug 19, 2025, 8:12 AM EDT - 26 days ago

Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

Jul 23, 2025, 8:00 AM EDT - 7 weeks ago

Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 10, 2025, 4:05 PM EDT - 2 months ago

Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

Jun 30, 2025, 3:15 PM EDT - 2 months ago

Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

Jun 23, 2025, 8:00 AM EDT - 2 months ago

Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

Feb 4, 2025, 9:25 AM EST - 7 months ago

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial

Jan 30, 2025, 8:00 AM EST - 8 months ago

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial

Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

Dec 4, 2024, 4:56 PM EST - 10 months ago

Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq

Dec 2, 2024, 7:00 PM EST - 10 months ago

Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq

Neuro-inflammation biotech Jupiter Neurosciences revises terms, removes warrants ahead of $15 million IPO

Aug 16, 2022, 5:48 PM EDT - 3 years ago

Neuro-inflammation biotech Jupiter Neurosciences revises terms, removes warrants ahead of $15 million IPO

Thenew52
Thenew52 Sep. 12 at 11:20 PM
$JUNS I'll just say that this is an opportunity for you to buy at a discount. Since I bought when the stock was even lower, I'm calm. So, don't let you continue missing this golden opportunity while I sit back and watch how this will reach $3 in a month.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 8:44 PM
$JUNS It stagnated at 1.52 and people are buying it at that same price. Doesn't that seem like a sign to you?
0 · Reply
Thenew52
Thenew52 Sep. 12 at 8:03 PM
$JUNS Well, we closed in the red after a volatile day. After Monday's pre-market, we'll see if it remains green or if it's best to sell and buy lower.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 3:23 PM
$JUNS Every time it falls it rises and yet you don't buy at the bottom?
0 · Reply
Thenew52
Thenew52 Sep. 12 at 2:31 PM
$JUNS In October it will reach 3 dollars
0 · Reply
Thenew52
Thenew52 Sep. 12 at 2:30 PM
$JUNS They want to buy cheap because they know it will reach $3.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 1:31 PM
$JUNS Opening at 1.59, I think we'll have a green day today.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 10:59 AM
$JUNS It has consolidated at 1.62 for now, but the really good stuff comes at the opening.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 10:04 AM
$JUNS What's going on here? The real price is still above 1.60, but it's 1.51 on Google and here.
0 · Reply
Thenew52
Thenew52 Sep. 12 at 9:19 AM
$JUNS 1.64 pre-market
0 · Reply
Thenew52
Thenew52 Sep. 12 at 12:00 AM
$JUNS
0 · Reply
Thenew52
Thenew52 Sep. 11 at 11:59 PM
$JUNS But what a beautiful day, we will continue to see that green that we like so much for a long time.
0 · Reply
Thenew52
Thenew52 Sep. 11 at 8:45 PM
$JUNS How much could this stock really reach this year? Probably between what is left in September and in October it will reach 2 to 3 dollars, between 3 and 4 dollars in November and in December if everything goes well probably 4 to 5 dollars. This would be without really explosive announcements, but if they announce some explosive surprise or some new catalyst, all this could end up doing double what I said.
0 · Reply
Thenew52
Thenew52 Sep. 11 at 8:40 PM
$JUNS There are two possible reasons why this stock has been in the green for a couple of days. 1. One or more insiders are accumulating ahead of a possible announcement. 2. The market simply has more confidence in this stock thanks to all its positive aspects.
0 · Reply
Thenew52
Thenew52 Sep. 11 at 8:38 PM
$JUNS I've got everything ready, I think it could reach $3 or a little more soon and then enter a "stagnation" phase until there's a new announcement.
0 · Reply
Thenew52
Thenew52 Sep. 11 at 8:07 PM
$JUNS A close at 1.56, and a volume of over 300k, it's very obvious that something is slowly brewing here.
0 · Reply
Thenew52
Thenew52 Sep. 11 at 6:18 PM
$JUNS
0 · Reply
Thenew52
Thenew52 Sep. 11 at 6:17 PM
$JUNS Next week we'll probably see this stock at $2, tomorrow it might reach $1.75 or more.
0 · Reply
Thenew52
Thenew52 Sep. 11 at 2:42 PM
$JUNS I'm surprised that even though it fell to 1.47, it went back to 1.55, and they still don't buy the dips? 🤨
0 · Reply
Thenew52
Thenew52 Sep. 11 at 1:42 PM
$JUNS
0 · Reply
Thenew52
Thenew52 Sep. 11 at 1:29 PM
$JUNS
0 · Reply
Thenew52
Thenew52 Sep. 11 at 1:26 PM
$JUNS The CEO's track record is better than that of other companies that have managed to achieve a +100% from one moment to the next. In his previous company, he achieved global approval for a drug and laid the groundwork for the same company to expand. Still, do you have doubts?
0 · Reply